{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011474","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.822617+00:00","generated_at":"2026-05-31T10:45:26.768517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS Neurosciences Q2 2024: Positive Phase 1a data for PMN310; secures up to $122.7M PIPE","bullets":["Phase 1a of PMN310 in Alzheimer's showed no SAEs; CSF levels >100x oligomer concentration, half-life ~25 days supporting monthly dosing.","PIPE financing closed July 2024 with initial $30.3M; up to $122.7M total tied to warrant milestones from healthcare specialist investors.","Cash and equivalents $1.0M at June 30, 2024 (down from $12.6M at Dec 31, 2023); subsequent PIPE strengthens balance sheet.","Net loss $2.6M for Q2 2024 vs $2.3M in Q2 2023; R&D expenses $1.6M (up $0.6M YoY) driven by PMN310 clinical costs.","Company expects to report topline results from all five cohorts in H2 2024 and initiate a Phase 1b trial in 100 AD patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011474","json":"https://secwatch.observer/filing/0001558370-24-011474.json","markdown":"https://secwatch.observer/filing/0001558370-24-011474.md","text":"https://secwatch.observer/filing/0001558370-24-011474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024011474/0001558370-24-011474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024011474/pmn-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:45:26.768517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}